伤痛康胶囊治疗胸胁扭挫伤的Ⅲ期临床试验

Phase Ⅲ Clinical Trials of SHANGTONGKANG Capsule for Sprain and Contusion at Thoracoflank

为评价伤痛康胶囊治疗急性胸胁扭挫伤的疗效和安全性 ,进行 期临床试验 ,结果显示试验组总有效率为 95 % ,对照组总有效率为 85 % ,试验组疗效优于对照组 ,说明伤痛康胶囊是一种治疗急性胸胁扭挫伤的安全有效药物。

To value the therapeutic efficiency and security of SHANGTONGKANG(STK)\ capsule for treating acute sprain and contusion at thoracoflank,the phase Ⅲ clinical trials were made.The result showed that the total effective rate of the observation group(G1) was 95%,the control group(G2) 85%.G1 was superior to G2.It indicates that STK capsule is one of the secure and effective drugs for treating acute sprain and contusion at thoracoflank.\;